The present invention relates to the use of agents (including heparin derivatives) for the prevention and/or treatment of CNS damage.

This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.

This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.

A rapid, minimally invasive biomarker assay is disclosed for distinguishing between ductal carcinoma in situ (DCIS) and early-stage invasive ductal carcinoma (IDC). The assay can be used for diagnostics and prognostics, and for supporting the development of treatments, procedures, protocols, and therapeutics aimed at preventing the invasive progression of breast cancer.